Type of the Paper (Article, Review, Perspective, etc.)

Title of the Paper (Be Concise and Informative)

Firstname Lastname 1, Firstname Lastname 2,\*, Firstname Lastname 2,\*

1 Affiliation 1

2 Affiliation 2

**\*** Correspondence: Firstname Lastname, Email: e-mail@e-mail.com; Tel.: +xx-xxx-xxx-xxxx; Firstname Lastname, Email: e-mail@e-mail.com; Tel.: +xx-xxx-xxx-xxxx.

ABSTRACT

The abstract should be an objective representation of the article. It must not contain results which are not presented in the main text. The word limit is 250 words. Do not include citations in the abstract. We encourage authors to use the following style of structured abstracts for research articles.

*Background*: Describe the context and purpose of the study.

*Methods*: Report briefly how the study was performed, main methods and statistical tests used.

*Results*: Summarize main outcomes of the study.

*Conclusions*: Indicate main conclusions and potential implications.

*Trial Registration*: For clinical trials only, add here the name of the trial registry, registration number and URL link.

KEYWORDS: keyword 1; keyword 2; keyword 3 (List here three to ten keywords specific to the article.)

ABBREVIATIONS (IF ANY)

MRI, magnetic resonance imaging; TEM, transmission electron microscopy; TGF, transforming growth factor

HOW TO USE THIS TEMPLATE

This template describes sections to be used in a research article. Review papers can have different sections but apply the same style.

INTRODUCTION (LEVEL 1 HEADING)

The introduction should explain the background of the study, the questions it aims to address, and how important it is. A concise literature review of key publications should be included. Please keep in mind that readers might be outside of your research field, so write the introduction as understandable as possible. If there are controversies or disagreements in the field, please mention them so that readers can get an overall view on the topic. The introduction should conclude with a statement on the aim of the study, and its contribution to the field.

MATERIALS AND METHODS

Materials and methods section should provide enough details so that others can replicate the study. Common procedures can be provided with a reference, but new protocols should be described in details. If the new protocol is complicated, we encourage authors to submit a separate Protocol type paper alongside the study, and they will be peer-reviewed together.

Researches involving animals or human subjects should indicate the details of ethical approval, including name of the ethics committee, project identification code and date of approval.

Statistical methods used in the study should be clarified in this section. The description should allow a knowledgeable reader with access to original data to judge its appropriateness and verify the results.

RESULTS

Results section should describe findings from the study arranged in a logical sequence without bias or interpretation. This section may be divided into subsections and subsubsections.

We encourage authors to make all relevant data from the study (including raw data, software, code, models, algorithms, *etc.*) available to readers, either through supplementary materials for small datasets or publicly available registries for large datasets. Please include name of the registry and link to data in Data Availability section below.

Formatting of Figures and Tables

All figures and tables should be cited in the main text as Figure 1, Table 1, *etc.*

|  |  |
| --- | --- |
| (**A**) | (**B**) |

Figure 1. Figures should be placed in the main text near to where they are cited the first time. Text inside the figure should be larger than 8 point, in Arial or Helvetica font type. Total size of the entire figure should not exceed one page. For multiple parts of a figure, they can be list as follows. (A) Description of content in this part of the figure. (B) Description of content in this part.

Table 1. Tables should be placed in the main text near to where they are cited for the first time.

|  |  |  |
| --- | --- | --- |
| Title 1 | Title 2 | Title 3 |
| Entry 1 | data | data |
| Entry 2 | data | data 1 |
| Entry 3 | data | data |

1 This is a footer for the table.

Title of Subsection (Level 2 Heading)

Main text begins here.

Main text continues here.

Title of subsubsection (level 3 heading)

Numbered lists can be formatted as follows:

1. First item
2. Second item
3. Third item

The bulleted lists can be formatted like this:

* First bullet
* Second bullet
* Third bullet

Main text continues here.

Main text continues here.

Formatting of Mathematical Equations

This is an example of the equation format:

|  |  |
| --- | --- |
| a = 1233565666, | (1) |

the text following an equation do not need to be a new paragraph. Please punctuate equations as regular text.

Main text continues here.

DISCUSSION

This section should explain the implication of the results and should place them into a broader context of the current literature. Discussion may contain subheadings to highlight important areas that are expanded on in the main text.

Title of Subsection

Title of subsubsection

Main text continues here.

CONCLUSIONS

This section should clearly and concisely describe the main conclusions of the work and their significance. You may also highlight limitations of the study and future research directions.

**ETHICAL STATEMENT**

**Ethics Approval**

Please add “The study was approved by the Institutional Review Board (or Ethics Committee) of NAME OF INSTITUTE (protocol code XXX and date of approval).” for studies involving humans. OR “Ethical review and approval were waived for this study due to REASON (please provide a detailed justification).” OR “Not applicable” for studies not involving humans or animals.

Also, informed Consent Statement should be included. Any research article describing a study involving humans should contain this statement. Please add "Regarding the Informed Consent Statement, informed consent was obtained from all subjects involved in the study" at the end of the Ethics Approval or in your text. OR “Patient consent was waived due to REASON (please provide a detailed justification).” OR “Not applicable.” for studies not involving humans. You might also choose to exclude this statement if the study did not involve humans.

**Declaration of Helsinki STROBE reporting guideline**

This study adhered to the Helsinki Declaration. The Strengthening the Reporting of Observational studies in Epidemiology (STROBE) reporting guideline was followed.

DATA AVAILABILITY

Please make a data availability statement for all research articles. Some examples are listed below:

* The dataset generated from (or analyzed in) the study can be found at [repository name and link].
* All data generated from the study are available in the manuscript or supplementary files.
* No data were generated from the study.
* The dataset of the study is available from the authors upon reasonable request.
* The dataset from the study is not available because [reason].

You may contact the editorial office for advice if you are not sure how to make the statement.

AUTHOR CONTRIBUTIONS

All authors should meet the authorship criteria listed in International Committee of Medical Journal Editors ([ICMJE](http://www.icmje.org/recommendations/)) guidelines. Individual author’s contributions should be provided in this section, for example: “Conceptualization, XX and YY; Methodology, XX; Software, XX; Validation, XX, YY and ZZ; Formal Analysis, XX; Investigation, XX; Resources, XX; Data Curation, XX; Writing—Original Draft Preparation, XX; Writing—Review & Editing, XX; Visualization, XX; Supervision, XX; Project Administration, XX; Funding Acquisition, YY.” Acquisition of funding; general supervision of a research group or general administrative support; and writing assistance, technical editing, language editing, and proofreading alone, do not qualify for authorship. Those contributors should not be listed as authors but they should be acknowledged in Acknowledgments section below.

CONFLICTS OF INTEREST

Authors are required to declare all conflicts of interest in relation to their work. Conflicts of Interest can be financial or non-financial, professional, or personal. It can arise in relationship to an institution, organization, or another person. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Where authors have no conflicts of interest, the statement should read “The author(s) declare(s) that they have no conflicts of interest”.

FUNDING

All sources of funding that supported the research should be declared in this section, for example: “This research was funded by [name of funder], grant number [xxx]”.

ACKNOWLEDGMENTS

In this section you can acknowledge any support given by others which is not covered by the author contribution or funding sections.

REFERENCES

All references should be numbered consecutively in order of appearance in main text, figures, tables and supplementary materials. References cited only in the supplementary materials should be listed at the end of the References section in main text. Citations of references in text should be identified using numbers in square brackets (e.g., “as discussed by [2]”; “as discussed elsewhere [2,3]”). The digital object identifier (DOI) should be included for all references where available.

Hapres uses “Vancouver” style, as outlined in the ICMJE sample references (<https://www.nlm.nih.gov/bsd/uniform_requirements.html>) with some variations on electronic materials. See following examples:

1. Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-6. doi: 10.1016/S0006-8993(02)02445-9
2. Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169(6):2257-61. doi: 10.1097/01.ju.00000  
   67940.76090.73
3. Ellingsen AE, Wilhelmsen I. [Disease anxiety among medical students and law students]. Tidsskr Nor Laegeforen. 2002 Mar 20;122(8):785-7. Norwegian.
4. Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2000;61(12):909-11. Retraction in: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2002;63(2):169.
5. Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis (US): Mosby; 2002.
6. Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wieczorek RR, editor. White Plains (NY, US): March of Dimes Education Services; 2001.
7. National Lawyer’s Guild AIDs Network (US); National Gay Rights Advocates (US). AIDS practice manual: a legal and educational guide. 2nd ed. San Francisco (US): The Network; 1988.
8. Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York (US): McGraw-Hill; 2002. p. 93-113.
9. Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York (US): Springer; 2002.
10. Christensen S, Oppacher F. An analysis of Koza’s computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin (Germany): Springer; 2002. p. 182-91.
11. Yen GG (Oklahoma State University, School of Electrical and Computer Engineering, Stillwater, OK, US). Health monitoring on vibration signatures. Final report. Arlington (VA, US): Air Force Office of Scientific Research (US), Air Force Research Laboratory; 2002 Feb. Report No.: AFRLSRBLTR020123. Contract No.: F496209810049.
12. Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI, US): Central Michigan University; 2002.
13. Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.
14. Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. Proc Natl Acad Sci U S A. Forthcoming 2002.
15. Bar DZ, Atkatsh K, Tavarez U, Erdos MR, Gruenbaum Y, Collins FS. Biotinylation by antibody recognition—A novel method for proximity labeling. bioRxiv 069187 [Preprint]. 2016 Aug 11. doi: 10.1101/069187
16. Alvarez R. Near optimal neural network estimator for spectral x-ray photon counting data with pileup. arXiv:1702.01006v1 [Preprint]. 2017 Feb 3. Available from: <https://arxiv.org/abs/1702.01006>. Accessed 2017 Feb 9.
17. Zheng LY, Guo XS, He B, Sun LJ, Peng Y, Dong SS, et al. Genome data from sweet and grain sorghum (*Sorghum bicolor*). GigaScience Database. 2011 Nov 12. doi: 10.5524/100012
18. The Mouse Tumor Biology Database. Available from: [http://tumor.  
    informatics.jax.org/mtbwi/index.do](http://tumor.informatics.jax.org/mtbwi/index.do). Accessed 2013 May 20.
19. Office of International Medicine|AMA. Available from: [https://www.ama-  
    assn.org/about/office-international-medicine](https://www.ama-assn.org/about/office-international-medicine). Accessed 2016 Dec 27.

How to cite this article:

Lastname F, Lastname F, Lastname F. Title of the Paper (Be Concise and Informative). Adv Geriatr Med Res. 2025, submitted for review.